<DOC>
	<DOCNO>NCT00622700</DOCNO>
	<brief_summary>The primary objective demonstrate effect teriflunomide ( HMR1726 ) ( 14 milligram per day [ mg/day ] 7 mg/day ) , comparison placebo , reduce conversion participant present first clinical episode consistent multiple sclerosis ( MS ) clinically definite multiple sclerosis ( CDMS ) . The secondary objective : - To demonstrate effect teriflunomide , comparison placebo , : - Reducing conversion definite multiple sclerosis ( DMS ) - Reducing annualized relapse rate ( ARR ) - Reducing disease activity/progression measure Magnetic Resonance Imaging ( MRI ) - Reducing accumulation disability least 12 week measure Expanded Disability Status Scale ( EDSS ) - Proportion disability-free participant assess EDSS - Reducing participant-reported fatigue - To evaluate safety tolerability teriflunomide - To evaluate pharmacokinetics ( PK ) teriflunomide - Optional pharmacogenomic testing aim assess association main enzyme system teriflunomide metabolism hepatic safety , potential association gene variation clinical outcome</brief_summary>
	<brief_title>Phase III Study With Teriflunomide Versus Placebo Patients With First Clinical Symptom Multiple Sclerosis</brief_title>
	<detailed_description>The study consist 4 period : - Screening period : 4 week , - Placebo-controlled treatment period : 108 week ( least 24 week participant experience conversion CDMS ) , - Extension treatment period ( without placebo-control ) : extension period continue teriflunomide commercially available participant 's country residence . - Post-treatment washout period : 4 week last treatment intake . The maximal duration study period per participant expect 116 week he/she continue extension treatment period .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>First acute subacute , welldefined neurological event consistent demyelination ( , optic neuritis confirm ophthalmologist , spinal cord syndrome , brainstem/cerebellar syndrome ) Onset MS symptom occur within 90 day randomization A screening MRI scan 2 T2 lesion least 3 millimeter ( mm ) diameter characteristic MS Clinically relevant cardiovascular , hepatic , neurological , endocrine major systemic disease Significantly impair bone marrow function Pregnancy nursing Alcohol drug abuse Use cladribine , mitoxantrone , immunosuppressant agent azathioprine , cyclophosphamide , cyclosporin , methotrexate mycophenolate enrollment Any known condition circumstance would prevent investigator 's opinion compliance completion study The information intend contain consideration relevant participant 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>MS</keyword>
	<keyword>Clinically Isolated Syndrome</keyword>
	<keyword>CIS</keyword>
	<keyword>CDMS</keyword>
	<keyword>relapse</keyword>
</DOC>